Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PALO ALTO, Calif., Nov. 1, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today the presentation of mechanistic studies on Telintra and related analogs at the 2011 Meeting of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.  Details of the presentation are as follows:

Novel Ezatiostat analogues disrupt binding of GSTP1 to all three major MAP kinases (JNK, ERK and p38) and exhibit context-dependent antitumor activity; Ali-Osman, F., Okamura, T., Turley, R., Barker, A.,  Keck, J.,  Laborde, E.,  Cai, D.,  Macsata, R.



Abstract B229 – PO 70, Therapeutic Agents: Small Molecule Kinase Inhibitors 2, Monday, November 14, 12:30-2:30 PM and 6:00-7:30 PM.



These studies were conducted by Professor Francis Ali-Osman, Director, Experimental Therapeutics Program, Duke Comprehensive Cancer Center, and expand our understanding of the novel mechanism of action of Telintra.  Telintra and related analogues, through their inhibition of the enzyme GSTP1, were able to affect the activity of all three major MAP kinases, signaling proteins that are critical for the control of cellular growth, differentiation and apoptosis.  Significant anti-tumor activity was also observed in human cancer cells derived from brain cancer, breast cancer and melanoma.  Telintra has demonstrated positive clinical activity in patients with myelodysplastic syndrome (Blood 2009, 113[26]:6533-6540; Cancer 2011, doi: 10.1002/cncr.26469), and is currently in clinical development (Clintrials.gov).

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.



RELATED LINKS
http://www.telik.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.